Literature DB >> 18188450

Role of Gas6 in erythropoiesis and anemia in mice.

Anne Angelillo-Scherrer1, Laurent Burnier, Diether Lambrechts, Richard J Fish, Marc Tjwa, Stéphane Plaisance, Rocco Sugamele, Maria DeMol, Eduardo Martinez-Soria, Patrick H Maxwell, Greg Lemke, Stephen P Goff, Glenn K Matsushima, H Shelton Earp, Marc Chanson, Désiré Collen, Shozo Izui, Marc Schapira, Edward M Conway, Peter Carmeliet.   

Abstract

Many patients with anemia fail to respond to treatment with erythropoietin (Epo), a commonly used hormone that stimulates erythroid progenitor production and maturation by human BM or by murine spleen. The protein product of growth arrest-specific gene 6 (Gas6) is important for cell survival across several cell types, but its precise physiological role remains largely enigmatic. Here, we report that murine erythroblasts released Gas6 in response to Epo and that Gas6 enhanced Epo receptor signaling by activating the serine-threonine kinase Akt in these cells. In the absence of Gas6, erythroid progenitors and erythroblasts were hyporesponsive to the survival activity of Epo and failed to restore hematocrit levels in response to anemia. In addition, Gas6 may influence erythropoiesis via paracrine erythroblast-independent mechanisms involving macrophages. When mice with acute anemia were treated with Gas6, the protein normalized hematocrit levels without causing undesired erythrocytosis. In a transgenic mouse model of chronic anemia caused by insufficient Epo production, Gas6 synergized with Epo in restoring hematocrit levels. These findings may have implications for the treatment of patients with anemia who fail to adequately respond to Epo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18188450      PMCID: PMC2176185          DOI: 10.1172/JCI30375

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  55 in total

1.  Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure.

Authors:  Francesco Locatelli; Pedro Aljama; Peter Bárány; Bernard Canaud; Fernando Carrera; Kai-Uwe Eckardt; Walter H Hörl; Iain C Macdougal; Alison Macleod; Andrzej Wiecek; Stewart Cameron
Journal:  Nephrol Dial Transplant       Date:  2004-05       Impact factor: 5.992

2.  Studies on lipids of red blood cells in phenylhydrazine-treated albino rats.

Authors:  S K Jain; D Subrahmanyam
Journal:  Indian J Biochem Biophys       Date:  1976-06       Impact factor: 1.918

3.  Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.

Authors:  J W Eschbach; J C Egrie; M R Downing; J K Browne; J W Adamson
Journal:  N Engl J Med       Date:  1987-01-08       Impact factor: 91.245

4.  The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade.

Authors:  G Manfioletti; C Brancolini; G Avanzi; C Schneider
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

5.  Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells.

Authors:  M J Koury; M C Bondurant
Journal:  Science       Date:  1990-04-20       Impact factor: 47.728

6.  Identification of the renal erythropoietin-producing cells using transgenic mice.

Authors:  P H Maxwell; M K Osmond; C W Pugh; A Heryet; L G Nicholls; C C Tan; B G Doe; D J Ferguson; M H Johnson; P J Ratcliffe
Journal:  Kidney Int       Date:  1993-11       Impact factor: 10.612

7.  Establishment and characterization of a human leukemic cell line with megakaryocytic features: dependency on granulocyte-macrophage colony-stimulating factor, interleukin 3, or erythropoietin for growth and survival.

Authors:  N Komatsu; H Nakauchi; A Miwa; T Ishihara; M Eguchi; M Moroi; M Okada; Y Sato; H Wada; Y Yawata
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

8.  Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis.

Authors:  C G Winearls; D O Oliver; M J Pippard; C Reid; M R Downing; P M Cotes
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321

9.  Quantitation of immunoglobulin associated with senescent erythrocytes from the rabbit.

Authors:  G L Dale; R B Daniels
Journal:  Blood       Date:  1991-03-01       Impact factor: 22.113

10.  A fibronectin matrix is required for differentiation of murine erythroleukemia cells into reticulocytes.

Authors:  V P Patel; H F Lodish
Journal:  J Cell Biol       Date:  1987-12       Impact factor: 10.539

View more
  41 in total

Review 1.  Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands.

Authors:  Thomas Schmidt; Isabel Ben-Batalla; Alexander Schultze; Sonja Loges
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 2.  The role of TAM family receptors and ligands in the nervous system: From development to pathobiology.

Authors:  Bridget Shafit-Zagardo; Ross C Gruber; Juwen C DuBois
Journal:  Pharmacol Ther       Date:  2018-03-04       Impact factor: 12.310

3.  Lipopolysaccharide inhibits macrophage phagocytosis of apoptotic neutrophils by regulating the production of tumour necrosis factor α and growth arrest-specific gene 6.

Authors:  Xueying Feng; Tingting Deng; Yue Zhang; Shaobo Su; Chiju Wei; Daishu Han
Journal:  Immunology       Date:  2010-10-29       Impact factor: 7.397

Review 4.  Erythroblastic islands: niches for erythropoiesis.

Authors:  Joel Anne Chasis; Narla Mohandas
Journal:  Blood       Date:  2008-08-01       Impact factor: 22.113

Review 5.  Immunobiology of the TAM receptors.

Authors:  Greg Lemke; Carla V Rothlin
Journal:  Nat Rev Immunol       Date:  2008-05       Impact factor: 53.106

Review 6.  The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer.

Authors:  Douglas K Graham; Deborah DeRyckere; Kurtis D Davies; H Shelton Earp
Journal:  Nat Rev Cancer       Date:  2014-12       Impact factor: 60.716

7.  During EPO or anemia challenge, erythroid progenitor cells transit through a selectively expandable proerythroblast pool.

Authors:  Arvind Dev; Jing Fang; Pradeep Sathyanarayana; Anamika Pradeep; Christine Emerson; Don M Wojchowski
Journal:  Blood       Date:  2010-09-01       Impact factor: 22.113

Review 8.  Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease.

Authors:  Bradley A Warady; Douglas M Silverstein
Journal:  Pediatr Nephrol       Date:  2013-09-05       Impact factor: 3.714

Review 9.  The erythroblastic island as an emerging paradigm in the anemia of inflammation.

Authors:  Jimmy Hom; Brian M Dulmovits; Narla Mohandas; Lionel Blanc
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

10.  TAM receptors and the regulation of erythropoiesis in mice.

Authors:  Hongmei Tang; Song Chen; Haikun Wang; Hui Wu; Qingxian Lu; Daishu Han
Journal:  Haematologica       Date:  2009-02-11       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.